Analytical Data
-
Gene name
CCND1
- Application
-
Alternative Names
B-cell lymphoma 1 protein ;BCL-1BCL-1 oncogene;PRAD1 oncogene
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P24385
-
Expression Region
1-295aa
-
Molecular Weight
37.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cyclin D1 (CCND1) is a key regulatory protein involved in cell cycle progression, particularly in the transition from the G1 phase to the S phase. Abnormal expression or mutation of CCND1 has been associated with various cancers, including breast, lymphoma, and colorectal cancer, making it a significant focus in oncological research. The gene encoding CCND1 is often subjected to genetic alterations such as amplifications and translocations, which can lead to elevated protein levels and aberrant cell proliferation. Given its pivotal role in cellular proliferation and tumorigenesis, the study of CCND1 recombinant protein has garnered attention for both its potential as a biomarker and its utility in therapeutic approaches. Researchers have been investigating the structural and functional characteristics of the CCND1 protein to understand its interactions with cyclin-dependent kinases (CDKs) and other regulatory proteins within the cell cycle machinery. By producing recombinant CCND1, scientists can explore its biochemical properties, develop specific inhibitors, and assess its role in various signaling pathways, thereby paving the way for targeted cancer therapies. Additionally, studying CCND1's interaction with other cellular components could elucidate mechanisms of resistance to existing treatments, ultimately improving therapeutic regimens for cancer patients. Overall, the investigation of CCND1 recombinant protein serves as a crucial step toward unraveling the complexities of tumor biology and enhancing cancer treatment strategies.
